Bay State startup Neograft closed an $11 million equity funding round in support of its vascular sleeve technology.
Neograft’s Angioshield device “creates a micro-fibrous, polymer sleeve intimately surrounding the outside surface of a harvested vein to mechanically reinforce and protect it from overdilation,” according to the company. The technology is not yet approved for clinical use.
Help employers find you! Check out all the jobs and post your resume.
